284665-40-3

Basic information

• Product Name: 4-(3,5-BIS-TRIFLUOROMETHYLPHENYL)THIAZOL-2-YLAMINE
• Synonyms: BUTTPARK 41\03-38;4-(3,5-BIS-TRIFLUOROMETHYLPHENYL)THIAZOL-2-YLAMINE;2-Amino-4-(3,5-bis(trifluoromethyl)phenyl)thiazole;4-(3,5-Bis(trifluoromethyl)phenyl)thiazol-2-amine;4-[3,5-bis(trifluoroMethyl)phenyl]-1,3-thiazol-2-aMine
• CAS NO: 284665-40-3
• Molecular Formula: C₁₁H₆F₆N₂S
• Molecular Weight: 312.23
• Mol File: 284665-40-3.mol

Chemical Properties

• Melting Point: 146.3-147.6°C
• Boiling Point: 338.793 °C at 760 mmHg
• Flash Point: 158.697 °C
• Appearance: /
• Density: 1.51 g/cm³
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-(3,5-BIS-TRIFLUOROMETHYLPHENYL)THIAZOL-2-YLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3,5-BIS-TRIFLUOROMETHYLPHENYL)THIAZOL-2-YLAMINE(284665-40-3)
• EPA Substance Registry System: 4-(3,5-BIS-TRIFLUOROMETHYLPHENYL)THIAZOL-2-YLAMINE(284665-40-3)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• Hazardous Substances Data: 284665-40-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-(3,5-Bis-Trifluoromethylphenyl)thiazol-2-ylamine is used as a chemical intermediate for the development of novel therapeutics due to its ability to bind to specific biological targets, which can lead to the creation of new drugs with improved pharmacokinetic and pharmacodynamic profiles.
Used in Agrochemical Industry:
4-(3,5-Bis-Trifluoromethylphenyl)thiazol-2-ylamine is used as a potential active ingredient in the development of new crop protection products, such as pesticides or fungicides, owing to its favorable physicochemical properties and potential to target specific biological processes in pests or pathogens.

Upstream product

• 17356-08-0 thiourea 
• 30071-93-3 3,5-bis(trifluoromethyl)phenyl methyl ketone 

Relevant articles and documents

THERAPEUTIC AGENT FOR CANCER

A medicament for the prevention and/or treatment of cancers and the like which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein A represents hydrogen atom or acetyl group, E represents a 2,5-di-substituted or a 3,5-di-substituted phenyl group, or a monocyclic or a fused polycyclic heteroaryl group which may be substituted, provided that the compound wherein said heteroaryl group is 1? a fused polycyclic heteroaryl group wherein the ring which binds directly to ―CONH― group in the formula (I) is a benzene ring, 2? unsubstituted thiazol-2-yl group, or 3? unsubstituted benzothiazol-2-yl group is excluded, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula ―O―A wherein A has the same meaning as that defined above and the group represented by formula ―CONH―E wherein E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula ―O―A wherein A has the same meaning as that defined above and the group represented by formula ― CONH―E wherein E has the same meaning as that defined above.

REMEDIES FOR NEURODEGENERATIVE DISEASES

A medicament for preventive and/or therapeutic treatment of neurodegenerative diseases such as Alzheimer's disease or the like which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein A represents hydrogen atom or acetyl group, E represents a 2,5-di-substituted or a 3,5-di-substituted phenyl group, or a monocyclic or a fused polycyclic heteroaryl group which may be substituted, provided that the compound wherein said heteroaryl group is 1○ a fused polycyclic heteroaryl group wherein the ring which binds directly to -CONH- group in the formula (I) is a benzene ring, 2○ unsubstituted thiazol-2-yl group, or 3○ unsubstituted benzothiazol-2-yl group is excluded, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula -O-A wherein A has the same meaning as that defined above and the group represented by formula -CONH-E wherein E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula -O-A wherein A has the same meaning as that defined above and the group represented by formula -CONH-E wherein E has the same meaning as that defined above.

INHIBITORS AGAINST THE ACTIVATION OF AP-1 AND NFAT

A medicament inhibiting the activation of AP-1 which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in the main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula -O-A wherein A has the same meaning as that defined above and the group represented by formula -X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula -O-A wherein A has the same meaning as that defined above and the group represented by formula -X-E wherein each of X and E has the same meaning as that defined above.

NF-KB ACTIVATION INHIBITORS

A medicament having inhibitory activity against NF-κB activation which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein A represents hydrogen atom or acetyl group, E represents a 2,5-di-substituted or a 3,5-di-substituted phenyl group, or a monocyclic or a fused polycyclic heteroaryl group which may be substituted, provided that the compound wherein said heteroaryl group is 1○ a fused polycyclic heteroaryl group wherein the ring which binds directly to ―CONH― group in the formula (I) is a benzene ring, 2○ unsubstituted thiazol-2-yl group, or 3○ unsubstituted benzothiazol-2-yl group is excluded, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula ―O―A wherein A has the same meaning as that defined above and the group represented by formula -CONH-E wherein E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula ―O―A wherein A has the same meaning as that defined above and the group represented by formula ― CONH―E wherein E has the same meaning as that defined above.